Groundbreaking genomic test could spare millions of breast cancer patients chemotherapy
A new international trial has demonstrated that a genomic test can accurately identify breast cancer patients who do not require chemotherapy. This breakthrough could spare millions of women from toxic side effects while maintaining effective treatment outcomes.
Why it matters
This represents a major advancement in personalized medicine that could significantly improve the quality of life for cancer patients globally.
Groundbreaking genomic test could spare millions of breast cancer patients chemotherapy | Breast cancer | The Guardian
The article reports on scientific trial results using objective, evidence-based language.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in